Regeneron Pharmaceuticals, Inc.
TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Last updated:
Abstract:
Methods for treating fibrodysplasia ossificans progressiva (FOP) in human subjects are provided. Such methods involve administering to a subject having FOP a therapeutically effective amount of an Activin A antagonist, such as an antibody against Activin A.
Status:
Application
Type:
Utility
Filling date:
8 Jan 2021
Issue date:
19 Aug 2021